Treatment

Phase 3Biologic

GSK

Treatment is one of 332 biologic programs targeting Arthritis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

331

Competitors

Pipeline

Status by Indication[3][1]

Indication

ArthritisActive, not recruiting

Lung CancerActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Latent Autoimmune Diabetes in AdultsActive, not recruiting

ElderlyCompleted

FunctionCompleted

Ovarian CancerNot yet recruiting

Actinic KeratosisRecruiting

Hepatitis BActive, not recruiting

ArthritisPreclinical

Active, not recruiting

Lung CancerPreclinical

Active, not recruiting

Type 2 Diabetes MellitusPreclinical

Active, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Latent Autoimmune Diabetes in AdultsPreclinical

Active, not recruiting

ElderlyPreclinical

Completed

FunctionPreclinical

Completed

Ovarian CancerPhase 2

Not yet recruiting

Actinic KeratosisPhase 3

Recruiting

Hepatitis BPhase 3

Active, not recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

EMRELIS

AbbVie

Phase 3

5 2

ONO-4538

Ono Pharmaceutical Co. Ltd

Phase 3

4 3

Enlonstobart

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

2 4

Treatment

GSK

Phase 3

1 5

Sac-TMT

Merck & Co.

Phase 3

1 6

Remeron

OOrganon and Co

Preclinical

1 7

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Bleeding

NCT06057675

Q4 2027

Phase 3Recruiting

Actinic Keratosis

NCT07137819

Post-ApprovalActive, not recruiting

Hepatitis B

NCT04780204

ApprovedRecruiting

Septic Shock

NCT05148286

Q4 2028

Phase 2Recruiting

Advanced Breast Cancer

NCT07810088

Q1 2029

Phase 2Not yet recruiting

Ovarian Cancer

NCT07339553

Clinical

Trials by Indication[1]

Capecitabine2 trials

Role of Early Versus Late Switch to Lapatinib-Capecitabine

Terminated· GSK logo

GSK··NCT01357863·3 enrolled

Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)

Completed· Novartis logo

Novartis··NCT01160094·288 enrolled

Fluorouracil1 trial

A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer

Terminated·—·Phase 1/2·NCT01671488·11 enrolled

Non-Small Cell Lung Cancer1 trial

VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02392455·817 enrolled

Arthritis1 trial

Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis

Completed·PProfessor Mikkel Østergaard··NCT02011386·53 enrolled

Cancer of the Lung1 trial

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

Completed· Pfizer logo

Pfizer·Phase 3·NCT01154140·343 enrolled

20 more indications

Hepatitis B1 trial

Effectiveness of Antiviral Treatment in Cirrhotic Patients with Low-level Hepatitis B Virus DNA Levels

Active, not recruiting·—·Phase 4·NCT04780204·600 enrolled

Latent Autoimmune Diabetes in Adults1 trial

Randomized Controlled Trial of Insulin Versus Tablets for Latent Autoimmune Diabetes in Adults (LADA)

Unknown status·—·N/A·NCT00776607·200 enrolled

Actinic Keratosis1 trial

Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis

Recruiting·AAresus Pharma GmbH·Phase 3·NCT07137819·280 enrolled

Elderly1 trial

Long-term Use of Proton Pump Inhibitors May Cause Vitamin B12 Deficiency in the Institutionalized Elderly

Completed·UUniversity of Delaware·N/A·NCT00843453·36 enrolled

Type 2 Diabetes Mellitus1 trial

Epidemiologic Survey to Describe the Current Medical Practice of General Practitioners Treating Subjects With Type 2 Diabetes Mellitus in Latina

Completed· GSK logo

GSK··NCT01387165·3,592 enrolled

Post-Traumatic Stress Disorder1 trial

Vilazodone for the Treatment of Posttraumatic Stress Disorder

Completed·SSouthern California Institute for Research and Education·Phase 4·NCT01715519·59 enrolled

Function1 trial

Pimecrolimus and Epidermal Barrier Function

Completed·UUniversity of Kiel·N/A·NCT01132079·15 enrolled

Giant Cell Arteritis1 trial

Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO

Unknown status·—·Phase 3·NCT03841734·8 enrolled

Ovarian Cancer1 trial

Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.

Not yet recruiting·PPeking University Third Hospital·Phase 2·NCT07339553·30 enrolled

Tuberculosis1 trial

NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02371681·262 enrolled

B-ALL1 trial

ThisCART19A Bridging to alloHSCT for R/R B-ALL

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 1·NCT05679687·20 enrolled

Ovarian Clear Cell Carcinoma1 trial

Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07239622·36 enrolled

Tics1 trial

Input of the Use of Indometacin in Gitelman Syndrome as Compared to Potassium Sparing Diuretics

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 1/2·NCT01146197·33 enrolled

Neuropathic Pain1 trial

Efficacy of an Intraoperative Periradicular Application of Platelet Rich Fibrin (PRF) on the Intensity of Residual Post-surgical Neuropathic Pain After a Surgery for Disc Herniation

Unknown status·UUniversity Hospital, Strasbourg, France·Phase 3·NCT05196503·60 enrolled

Lung Cancer1 trial

Survival Outcomes of Lung Cancer

Recruiting·HHunan Province Tumor Hospital··NCT03647098·20,000 enrolled

Cystic Fibrosis1 trial

Safety, Efficacy, and Feasibility of High-dose Cholecalciferol in Pediatric Patients With Cystic Fibrosis

Completed·JJohns Hopkins All Children's Hospital·Phase 2·NCT02613884·26 enrolled

Multiple Myeloma1 trial

Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma

Unknown status·SShenzhen Second People's Hospital·Phase 1·NCT03767725·10 enrolled

Bleeding1 trial

Subcutaneous Tranexamic Acid in Nasal Mohs Local Flap Reconstruction: Perioperative Bleeding, Edema, and Ecchymosis

Recruiting·VVanderbilt University Medical Center·Phase 2·NCT06057675·100 enrolled

Advanced Breast Cancer1 trial

A Multicenter, Single-arm, Phase II Clinical Study of Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT07810088·40 enrolled

Septic Shock1 trial

Albumin and Crystalloid Administration in Septic Shock (ALCAMIST): Multi-center, Open Labelled Randomized Controlled Trial

Recruiting·AAsan Medical Center·Approved·NCT05148286·2,426 enrolled

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for Treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: GSK

Treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q4 2028

Q1 2029

Trials by Indication[1]

Capecitabine2 trials

Fluorouracil1 trial

Non-Small Cell Lung Cancer1 trial

Arthritis1 trial

Cancer of the Lung1 trial

Hepatitis B1 trial

Latent Autoimmune Diabetes in Adults1 trial

Actinic Keratosis1 trial

Elderly1 trial

Type 2 Diabetes Mellitus1 trial

Post-Traumatic Stress Disorder1 trial

Function1 trial

Giant Cell Arteritis1 trial

Ovarian Cancer1 trial

Tuberculosis1 trial

B-ALL1 trial

Ovarian Clear Cell Carcinoma1 trial

Tics1 trial

Neuropathic Pain1 trial

Lung Cancer1 trial

Cystic Fibrosis1 trial

Multiple Myeloma1 trial

Bleeding1 trial

Advanced Breast Cancer1 trial

Septic Shock1 trial

References

Drug Info

Quick Facts

Related News